PT Pratapa Nirmala-Fahrenheit

What PT Pratapa Nirmala-Fahrenheit does

PT Pratapa Nirmala-Fahrenheit is a privately held, for-profit pharmaceutical company headquartered in Jakarta Pusat, Indonesia, with a workforce of 501 to 1,000 employees as of the latest available data. The firm has been in continuous operation since its founding in 1988, making it a long-tenured participant in the Indonesian pharmaceutical sector. Its corporate website at fahrenheit.co.id could not be interrogated beyond a verification/loading page, and consequently no specific product portfolio, therapeutic categories, manufacturing capabilities, distribution channels, regulatory approvals, or pipeline details are disclosed in the available source material.

The company's leadership comprises at least one named executive, Peter Sutandar, serving as Managing Director. Beyond the managing-director appointment, no additional management team, board, scientific advisory, or ownership/governance details have been disclosed. The company is registered as aPerseroan Terbatas (PT), the standard Indonesian limited liability entity form, and operates under a localized.id domain, consistent with domestic Indonesian commercial activity rather than international expansion.

No revenue, pricing, customer segmentation, partnership, funding, M&A, certification, patent, or technology-stack data is present in the source material. As a result, the business model (manufacturing vs. distribution vs. branded marketing vs. generics), go-to-market motion, pricing mechanics, and revenue stream composition cannot be characterized from the evidence available. The firm should be treated as a data-thin target pending primary-source diligence on financial statements, BPOM (Indonesian FDA equivalent) product registrations, and shareholder structure.

Based on industry benchmarks for Indonesian mid-sized pharmaceutical firms of 500-1,000 employees with three-plus decades of operating history, revenue is plausibly situated in the $10M-$50M band, though no disclosed financials exist to confirm this. Customer concentration, AI capability, and expansion signals are all unobservable from the inputs and are flagged accordingly in their respective fields.

Name

PT Pratapa Nirmala-Fahrenheit

Legal name

PT Pratapa Nirmala-Fahrenheit

Website

https://fahrenheit.co.id

Company type

Private

Founded year

1988

Headcount range

501–1,000 employees

Short description

PT Pratapa Nirmala-Fahrenheit is a privately held Indonesian pharmaceutical company founded in 1988, headquartered in Jakarta Pusat, with 501 to 1,000 employees serving the domestic healthcare market under the leadership of Managing Director Peter Sutandar.

Ownership category

akta.pro rank

Headquarters

HQ city

Jakarta Pusat

HQ country

Indonesia

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations

Core offering

PT Pratapa Nirmala-Fahrenheit is an Indonesian pharmaceutical company engaged in the manufacturing and/or distribution of pharmaceutical products. Founded in 1988 and headquartered in Jakarta Pusat, the company operates as a private, for-profit entity with an employee base of 501–1,000, serving the Indonesian healthcare market.

Product overview

No product information available. The source data contains only a loading/verification page ("One moment, please...") from fahrenheit.co.id with no substantive content about products, services, or company offerings.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Products

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Broad incumbents

• PT Kimia Farma: State-owned Indonesian pharmaceutical manufacturer and pharmacy chain with manufacturing, distribution, and retail operations. Directly comparable as a domestic pharma manufacturer serving the same BPOM-regulated market and customer base.
• PT Kalbe Farma: Indonesia's largest pharmaceutical company and a broad incumbent across prescription, OTC, consumer health, and distribution. Comparable on domicile (Indonesia), manufacturing-vs-distribution mix, and target customers (BPJS, hospitals, retail pharmacies), though materially larger and publicly listed.

Direct peers

• PT Indofarma (Indofarma Global Medika): Indonesian state-linked manufacturer of finished pharmaceuticals. Comparable as a domestic finished-dose manufacturer with similar headcount scale and product positioning in generics/ethical categories.
• PT Dexa Medica: Privately-held Indonesian pharmaceutical group with manufacturing of branded generics and ethical products. Closely comparable on scale, ownership profile (private), and product mix targeting domestic hospital and retail channels.
• PT Sanbe Farma: Indonesian pharma manufacturer of finished dosage forms with manufacturing sites and a broad domestic distribution network. Directly comparable as a mid-sized domestic manufacturer competing for the same BPOM-authorized product portfolios.
• PT Ethica Industri Farmasi: Indonesia-based pharmaceutical manufacturer of generics and licensed products. Directly comparable as a domestic finished-dose manufacturer competing in the same regulatory and customer environment.
• PT Combiphar: Indonesian pharmaceutical manufacturer focused on prescription and consumer health products. Comparable on domestic manufacturer status, BPOM-licensed manufacturing, and mid-tier scale.
• PT Phapros: Indonesian pharmaceutical manufacturer of generic and ethical products with BPOM-licensed operations. Comparable as a domestic finished-dose manufacturer of similar scale targeting the same Indonesian market.
• PT Mensa Bina Sukses: Privately-held Indonesian pharmaceutical manufacturer covering finished-dose products. Comparable on ownership profile, domestic manufacturing focus, and mid-sized scale.

Regional players

• PT Prodia Widya Husada: Indonesian healthcare company adjacent to pharma through diagnostics and clinical laboratory services. Included as a regional healthcare-life-sciences comparable rather than a direct manufacturing peer.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• Facebookfacebook.com/1687247151522485

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PT Pratapa Nirmala-Fahrenheit